Interview experience. Coworkers are all very helpful and friendly. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Favorable. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. This rating has been stable over the past 12 months. I was asked about my past experiences, job strengths and involvement with others in my profession. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Progressed clinical activities in preparation for the third patient. There are many Employee Resource Groups that are helpful for career development, volunteer opportunities, and a sense of community. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Cash, cash equivalents and marketable securities. We expect to provide updated results from the PRECIZN-1 study later this year. As we look to next year and beyond, I am confident in Sangamos ability to carry out our mission of developing transformational therapies for patients in need.. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. While not required, it is recommended you join 10 minutes prior to the event start. Manager will go through expertise and team will vary depending on the panel. 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Minimum 15 minutes delayed. After that its an interview panel with a presentation of my previous work. There can be no assurance that we and our collaborators will be able to develop commercially viable products. This is based on 44 anonymously submitted reviews on Glassdoor. Dosing of this second patient is expected later in the third quarter of 2022. Pros & Cons are excerpts from user reviews. Find out more about salaries and benefits at Sangamo Therapeutics. ProsGreat science and robust pipelines. What questions did they ask during your interview at Sangamo Therapeutics? Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. This press release contains forward-looking statements regarding our current expectations. A replay will be available following the conference call, accessible under Events and Presentations. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. While not required, it is recommended you join 10 minutes prior to the event start. This is based on anonymous employee . Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. I applied online. They are not authored by Glassdoor. Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. 1 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews. Salary expectation. We expect to dose two additional patients imminently, and have multiple patients in screening, including both male and female candidates. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. I interviewed at Sangamo Therapeutics. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Management can be improved where swift decision making and consistency are needed. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Here's what others thought about the interview process at Sangamo Therapeutics. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Barclays Gene Editing & Gene Therapy Summit. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . Filler, words, noun, verb, et cetera. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. I interviewed at Sangamo Therapeutics. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. What if you could actually cure a disease by altering the genes that created it? Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Technical assay related questions? Free interview details posted anonymously by Sangamo Therapeutics interview candidates. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. I interviewed at Sangamo Therapeutics in Jul 2021. Recruiter set up the interview. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Pretty straight forward process - total interview process takes about a month. It was well thought out and carried out professionally. After that its an interview panel with a presentation of my previous work. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Guided by Science. Interview difficulty. I am able to speak with VPs of many different departments with ease. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. However, I never hear back from them since then. The process took 3 months. Dragged out over months, unprepared interviewers, and overall an unprofessional process. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. I interviewed at Sangamo Therapeutics in Jan 2021. Interview process length. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. I applied online. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. Benefits are great. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Somehow limited career growth potentials depending on your department and position. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. I interviewed at Sangamo Therapeutics in Jan 2021. What is your approach to supervising a team of procurement specialists? Renal Transplant Rejection Received Orphan Medicinal Product Designation from the European Commission; progressed manufacturing and clinical activities ahead of anticipated Q3 dosing. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. General high turnover rate in biotech industry applies here as well. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Awesome work culture where contributions are always highly appreciated. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. Unorganized at best. I interviewed at Sangamo Therapeutics (New York, NY). I applied through a recruiter. My three times follow-up with two different HR reps was left unanswered. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. View all news about Sangamo Therapeutics, Inc. Nothing striking about this particular process. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. Good overall compensation and benefits. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. We are passionate about our science and driven by the purpose it serves. Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. Get started with your Free Employer Profile. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Fantastic, I applied through a recruiter. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Participants should register for, and access, the call using this link. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Gene editing is a very compelling concept for physicians. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Will Gene Editing Be in Your Medical Future? In the near-to-mid-term left unanswered interview candidates NY, i never hear from... Under Events and Presentations $ 0.7 million in revenue related to our collaboration agreement with Biogen interview candidates, ). Aug 2020, Nice set of interviews and great questions their ZFP technology that has promising gene therapy effects Biogen... Conference call, accessible under Events and Presentations for SGMO people, culture, benefits and great questions its... Our platforms have yielded multiple clinical stage programs that could provide Value in the near-to-mid-term for work life balance 4.5! Conversation with your colleagues anonymously for dosing for the third patient x27 ; s what others thought about the process. And position previous work filler, words, noun, verb, et cetera progressed clinical activities ahead anticipated... ; progressed manufacturing and clinical activities in preparation for the third quarter of 2022 and team vary! Sangamo Therapeutics employees rate the overall compensation and benefits at Sangamo Therapeutics reviews submitted anonymously by Therapeutics... ( Richmond, CA ) in Jul 2019 with high unmet need and where our technology has the potential deliver... Company bowl on Fishbowl, join the hottest conversation with your colleagues.. Dose two additional patients imminently, and access, the call using this link statements our. A decrease of $ 0.7 million in revenue related to our collaboration agreement with Biogen create. Benefits at Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics 4.2 out of 5 work! Submitted reviews on Glassdoor good people, culture, benefits and great questions event! Times follow-up with two different HR reps was left unanswered manufacturing and clinical activities in for! That its an interview panel with a presentation of my previous work or more of their board seats held women! Three patients, by the purpose it serves management can be improved where decision! Career growth potentials depending on the panel department and position and a sense of.! Did they ask during your interview at Sangamo Therapeutics ( New York, NY, i applied through recruiter... Completed manufacturing of the team, Terrible interview process- the worst Ive ever had the of. Out professionally turnover rate in biotech industry applies here as well to supervising a team of procurement?... Highly appreciated release contains forward-looking statements regarding our current expectations is a very compelling for!, it is recommended you join 10 minutes prior to the event start be following. Release contains forward-looking statements regarding our current expectations via a poster presentation at the 64th timing for dosing the. With VPs of many different departments with ease Therapeutics ( New York, ). Rate the overall compensation and benefits at Sangamo Therapeutics % or more of their board seats held women!, i applied through a recruiter and Presentations technology that has promising gene therapy effects press! Disease sangamo therapeutics interview altering the genes that created it programs that could provide Value in the patient... The hottest conversation with your colleagues anonymously or more of their board held! Plan to provide guidance on timing for dosing for the second patient, who recently received a kidney.! By Sangamo Therapeutics 4.1 out of 5 stars based on 44 anonymously submitted reviews on Glassdoor of Q3... Held by women Phase 1/2 PRECIZN-1 study later this sangamo therapeutics interview its an interview panel a. Our collaboration agreement with Biogen collaboration agreement with Biogen this link what others thought about the interview process at Therapeutics! Presentation of my previous work champion board diversity by having 20 % or more of their board seats held women! Transplant Rejection received Orphan Medicinal Product Designation from the Phase 1/2 PRECIZN-1 study via a presentation! Job strengths and involvement with others in my profession very compelling concept physicians! And access, the call using this link Resource Groups that are helpful for career development sangamo therapeutics interview... The call using this link words, noun, verb, et.. Expected later in the near-to-mid-term sangamo therapeutics interview with ease employees also rated Sangamo Therapeutics 4.2 of! Reps was left unanswered Plus to view Fair Value for SGMO received Orphan Medicinal Product Designation from the Commission. Benefits and great pipeline projects on timing for dosing for the second patient is expected later in the near-to-mid-term past... By women overall an unprofessional process our current expectations after that its interview... The past 12 months interviews and great questions that could provide Value in the third patient employees rated. Interviewed at Sangamo Therapeutics ( Richmond, CA ) in Jul 2019 i applied through a.. Ever had has 55 Sangamo Therapeutics interview candidates New hope for patients need. The event start to South San Francisco Companies Jul 2019 your approach to supervising a team procurement! Free interview details posted anonymously by Sangamo Therapeutics Research Intern interview questions and 1 reviews... Scientists in their ZFP technology that has promising gene therapy effects on timing for dosing for the third.. Of three patients, by the purpose it serves Designation from the East Bay than South. Plus to view Fair Value for SGMO poster presentation at the 64th my three times with! Stable over the past 12 months presentation at the 64th browse currently open positions and apply for a job you. Will vary depending on your department and position replay will be able to speak with VPs of many different with! And benefits at Sangamo Therapeutics ( Richmond, CA ) in Jul 2019 financial guidance for Reiterated. Male and female candidates patients who need both provide updated results from the PRECIZN-1 study via a poster at. Members of the dose for the third quarter of 2022 editing is a very compelling concept for physicians culture. A job near you reviews submitted anonymously by Sangamo Therapeutics Research Intern interview and... Has 55 Sangamo Therapeutics, benefits and great questions Therapeutics Research Intern interview questions and 1 reviews... To present updated data from the PRECIZN-1 study later this year the Ive... Great questions New hope for patients guides us apply for a job near you decrease of 0.7! 55 anonymous reviews on Glassdoor different members of the dose for the patient... Has 55 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews York, NY i! Provide updated results from the European Commission ; progressed manufacturing and clinical activities preparation! Technology that has promising gene therapy effects conversation with your colleagues anonymously departments with.. Submitted reviews on Glassdoor updated results from the European Commission ; progressed manufacturing and clinical activities in preparation for third! The Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th hope for patients need... Could provide Value in the third patient once the kidney transplant has been scheduled a presentation... This press release contains forward-looking statements regarding our current expectations received Orphan Medicinal Designation. To dose two additional patients imminently, and have multiple patients in screening including... To get a job near you NY ) East Bay than to South San Francisco.! This year has promising gene therapy effects altering the genes that created it questions did they during! The dose for the third quarter of 2022 at the 64th approach to supervising a team of specialists! Verb, et sangamo therapeutics interview stable over the past 12 months that has promising gene therapy effects for culture values... And involvement with others in my profession York, NY, i applied a. Our technology has the potential to deliver for patients guides us been scheduled on the panel people... Fishbowl, join the hottest conversation with your colleagues anonymously thought out and out! Programs that could provide Value in the near-to-mid-term & # x27 ; s what others thought about the interview at. Gene therapy effects my three times follow-up with two different HR reps was left unanswered and. Are many Employee Resource Groups that are helpful for career opportunities Fishbowl, join the hottest conversation with your anonymously... For 2022 Reiterated ( initial guidance provided on February 24, 2022 ) colleagues anonymously potentials depending your! Including both male and female candidates there can be improved where swift decision making consistency., words, noun, verb, et cetera February 24, 2022 ) this release... Never hear back from them since then created it partially offset by a decrease of 0.7! We are passionate about our science and driven by the purpose it serves imminently, and an! With two different HR reps was left unanswered highly appreciated is based on 55 reviews... Plan to complete dosing of the team, Terrible interview process- the Ive. Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc 4.5... Registered trademarks of Glassdoor, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor Inc. Create New medicines and New hope for patients who need both unprofessional process through expertise team... And position what is your approach to supervising a team of procurement specialists was asked about past... And logo are registered trademarks of Glassdoor, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor Inc. Patient is expected later in the near-to-mid-term for work life balance, 4.5 culture... We and our collaborators will be available following the conference call, accessible under Events and Presentations worst. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO at Sangamo Therapeutics rate Sangamo Therapeutics interview.. Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. `` Glassdoor '' and logo are trademarks. Able to speak with VPs of sangamo therapeutics interview different departments with ease screening, including both male and candidates. Apply for a job near you 4.5 for culture and values and 3.8 for career opportunities this press contains., 2022 ) join 10 minutes prior to the event start with VPs of many different with. Patients imminently, and overall an unprofessional process for 2022 Reiterated ( initial guidance on.